This is a standard clinical update with no data readout — expect minimal stock reaction. Monitor upcoming medical conference presentations for initial efficacy data from Cohorts 2 and 3, which could be a catalyst later in 2026.
Price Chart
Executive Summary
Perspective Therapeutics announced first patient dosing in two new cohorts of its Phase 1/2a trials for [212Pb]VMT-α-NET (neuroendocrine tumors) and [212Pb]PSV359 (solid tumors). This is a routine clinical milestone with no new efficacy or safety data released, and the stock has historically not reacted positively to such neutral updates.
Key Facts
- First patient dosed in Cohort 4 of Phase 1/2a trial for [212Pb]VMT-α-NET in SSTR2-positive neuroendocrine tumors, testing a front-loaded 20 mCi cumulative dose regimen.
- First patient dosed in Cohort 3 of Phase 1/2a trial for [212Pb]PSV359 in FAP-α-expressing solid tumors, receiving up to four 6.0 mCi doses every eight weeks.
- No new efficacy or safety data were released; prior interim data (cut-off March 4, 2026) was presented at AACR 2026.
- Pending efficacy data for remaining patients in Cohort 2 and eight patients in Cohort 3 of the VMT-α-NET trial, with submissions for medical conferences planned for 2026.
Financial Impact
No financial data disclosed; clinical milestone with no revenue impact.
Risk Factors
- Clinical trial failure or disappointing efficacy/safety data in pending cohorts.
- Cash burn rate and need for future capital raises given pre-revenue status.
- Regulatory and manufacturing risks for radiopharmaceutical production.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3296436 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $2.28 | awaiting T+20 | — | $1.23 (−46.05%) |
Oct 8, 2026 18d ago | 8-K | $2.71 | awaiting T+20 | — | $1.23 (−54.61%) |
Oct 2, 2026 24d ago | Press Release | $2.76 | awaiting T+20 | — | $1.23 (−55.43%) |
Sep 14, 2026 6w ago | 8-K | $2.92 $2.52 | ▼ −13.70% | ▼ −15.96% | $1.23 (−57.88%) |
Sep 11, 2026 6w ago | Press Release | $2.81 $2.66 | ▼ −5.34% | ▼ −7.21% | $1.23 (−56.23%) |
Sep 8, 2026 6w ago | Insider Cluster | $2.99 $2.46 | ▼ −17.73% | ▼ −19.67% | $1.23 (−58.86%) |
Sep 4, 2026 7w ago | Insider Cluster | $3.12 $2.36 | ▼ −24.36% | ▼ −26.07% | $1.23 (−60.58%) |
Sep 4, 2026 7w ago | Insider Cluster | $3.12 $2.36 | ▼ −24.36% | ▼ −26.07% | $1.23 (−60.58%) |
Aug 10, 2026 10w ago | 8-K | $3.18 $2.99 | ▼ −5.97% | ▼ −4.92% | $1.23 (−61.32%) |
Jul 17, 2026 14w ago | Press Release | $2.99 $3.20 | ▲ +7.02% | ▲ +2.58% | $1.23 (−58.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers